Those Quintiles IPO murmurs from last fall are ramping up again, but this time the rumors have teeth. Both Bloomberg and Reuters report that the CRO giant's private equity masters are actively interviewing banks to handle a Wall Street debut.
Drug-development specialist Xceleron is partnered with Crystal Pharmatech, and the two plan to pool their early-stage resources and offer clients quick bioavailability data for their compounds.
Almac has completed its knowledge transfer partnership with Belfast's Queens University, a pairing designed to boost the CDMO's biocatalysis business.
Japanese corporate giant Mitsui likes what it sees in the Indian CMO market, deciding to buy a nearly 30% stake in API manufacturer Arch Pharmalabs for $68 million.
U.K. drug giant GlaxoSmithKline has stretched its payment schedule for contractors from 60 days to as much as 95, The Daily Telegraph reports, a move that has CROs and suppliers accusing the company of corporate greed.
Covance has formed an alliance with Royal Liverpool and Broadgreen University Hospitals NHS Trust to conduct early clinical trials for biotech and pharma clients.
Clinipace has revamped its eClinical data platform, TEMPO, saying its new offering rolls disparate IT applications into one, allowing clients to cut down the cost and complexity of their clinical trials.
Quintiles has secured accreditation from the College of American Pathologists for its Mumbai, India, lab, making it the first on the continent to receive the mark.
As Big Pharma looks to tap the burgeoning drug market in China, companies are realizing they can't bulldoze in with U.S.-approved drugs and expect a red carpet. Instead, firms such as Vertex and AstraZeneca's MedImmune are looking to partner up with local expertise to speed their way to capitalization.
Parexel CEO Josef von Rickenbach will serve as chairman of industry group ACRO this year, succeeding PharmaNet CEO Jeffrey McMullen.
In India, drug-related clinical trial deaths rose in 2012, and sponsors and CROs remain loath to pay compensation to families.
Fresh off raising $12 million in Series B financing, goBalto has lured a major CRO with its cloud-based clinical development platform, signing a deal with INC Research.
Catalent Pharma Solutions is looking to expand its North Carolina-based inhalant unit, investing $20 million to expand the business' drug development, delivery and supply capabilities.
Indian CRO GVK Biosciences has signed a deal to co-develop cancer drugs with Onconova Therapeutics, using GVK's discovery platform to advance two of the drugmaker's targets to the clinical stage.
Contract manufacturer JHP Pharmaceuticals is now the property of private equity giant Warburg Pincus, as the company is spending $195 million to buy the CMO.
Australian CRO Clinical Network Services has acquired New Zealand's Beltas, a former partner and provider of wide-ranging trial services.
The clamor for reform of India's clinical trial regulations has reached a fever pitch over the past year, and now the country's Supreme Court is ordering the Health Ministry to keep a close eye on applications for new studies.
Getting trial participants to adhere to medication schedules can be a vexing problem for investigators, and, looking to address the problem, WCCT Global has partnered with Verified Clinical Trials to improve the latter's registry.
Questcor Pharmaceuticals has inked a deal to acquire Canadian CMO BioVectra for $50.7 million, buying a company that manufactures APIs, chemical intermediates and bioprocessing reagents.
Cellular Dynamics has struck a deal with AstraZeneca, agreeing to provide stem cells for AZ's drug-discovery efforts.